

Quantitative Imaging Excellence for Research and Clinical Trials

*We develop, validate and apply
imaging biomarkers for evaluating
musculoskeletal tissue pathology
and its response to treatment*

3D MRI of the Knee with the
Patellar & Tibial Cartilage
Thickness Color-Coded.

Journal Cover Award
Nature Rheumatology
Reviews (NRR) 2014

*We help make your research and
structure-modifying (DMOAD) clinical
trials faster, more efficient, and more
meaningful—in compliance with
regulatory requirements.*

CORE CAPABILITIES

- Cartilage morphometry (thickness, volume, surface areas, denuded areas)
- Cartilage composition relaxometry (e.g., T2)
- Meniscus morphometry (incl. position)
- Bone, muscle & adipose tissue morphometry (mass and shape)
- Hoffa fat pad (IPFP) morphometry & radiomics (signal & texture ≈ synovitis)
- Effusion synovitis morphometry
- Manual & fully automated (AI-based) analysis for these & other MSK structures.

**Book a 30-min Imaging Biomarker
Feasibility Call by E-mail & Ask for our
Regulatory Documentation Pack**

Visit our Web & LinkedIn Pages



Chondrometrics GmbH

Ludwig-Zeller-Strasse 12
D-83395 Freilassing, Germany
Email: info@chondrometrics.de

More information:



EXECUTIVE & STRATEGY TEAM



**Dr. Wolfgang
Wirth, PhD**

CEO,
CTO



**Prof. Dr. Felix
Eckstein, MD**

CMO, BD,
Medical Affairs



**Dr. Susanne
Maschek, PhD**

COO,
Education



**Prof. Dr. Reinhard
Putz, MD**

Governance,
Vice President





OUR JOURNEY

- Founded 2003 and headquartered in Freilassing (near Salzburg)
- >60 funded academic grants & subcontracts from 9 countries
- >10 industry-initiated clinical trials
- 50.000+ (human & animal) joints read
- **Your trial benefits from decades of experience and extensive prior data**

OUR EXPERTISE

- Class IIa Medical Device software platform (EU MDR 2017/745, Annex IX)
- EN ISO 13485:2021 certified QMS, compliant with GCP, 21 CFR Part 11, and relevant industry standards
- 200+ journal publications & 40.000+ citations (HF > 100)
- **Regulatory compliance for your trial**



COMPETITIVE EDGE


- 20+ years industry expertise
- Strong SAB of OA experts
- Quality-controlled manual gold-standard and technically/clinically validated, fully automated segmentation, using AI (CNN) technology
- **Scalable automated analysis for your trial, with economic benefits**



OUR MOTIVATION

- More than 500 million people world-wide live with osteoarthritis (OA), a major cause of pain and disability
- No approved drug (DMOAD) therapy currently exists for effectively modifying joint structural pathology in OA
- **To provide imaging biomarkers that accelerate your clinical development program of disease-modifying therapy**

Oblique Anterior View of the Knee Displaying Various Joint Tissues in Color



OUR VISION

- To establish imaging biomarkers as regulatory-accepted surrogate endpoints of clinical outcomes
- To establish AI-powered automated analysis of joint tissues & responsive measures of structural pathology
- **To advance quantitative imaging to make your clinical trials efficient, meaningful, and cost-effective**